The global vaccines sales in 2009 were $ 26 billion as compared to $24 billion in 2008 and $18.5 billion in 2007. Pandemic influenza vaccines were the best selling vaccines with sales of over $ 5 billion. Prevnar was the top selling vaccine brand with sales of $ 3 billion followed by Gardasil at $ 1.66 billion. GSK Hepatitis and Infantrix/Pediatrix Vaccines and Sanofi Aventis Pasteur Fluzone Influenza Vaccine each with sales of $ 1.2 billion were the joint 3rd top vaccines by sales. The polio vaccine IPOL from Sanofi Aventis Pasteur was the sixth vaccine to have sales of $ 1 billion in 2009. GSK, Sanofi Aventis, Merck, Pfizer (Wyeth) and Novartis were the global top five vaccine companies. More vaccines like RotaTeq, Rotarix and Cervarix are likely to reach sales of $ 1 billion in the next few years. The market for other vaccines declined due to economic turmoil, stockpiling, weak dollar and shift in staff, marketing, capacity to influenza vaccines. This is the first and earliest report providing 2009 vaccine market, sales and ranking and beat out the commercial reports by several months.
When Lipitor goes generic in a few months, Prevnar/Prevnar 13 will be PFE’s largest-selling franchise. (Enbrel will have higher in-market sales than the Prevnar franchise, but PFE books Enbrel sales outside North America only.)
Market Data 
Markets 
AI
